Procurement comparison
US Peptides Legit Review 2026: Comparison Table
| Supplier Category | Regulatory Status | Batch Testing Verification | Typical Purity Documentation | Legal Risk to Researcher | Operational Stability | Professional Assessment ||—|—|—|—|—|—|| US Peptides (defunct 2024) | Tier 3 grey-zone supplier. No FDA regi
Review the documented criteria directly; this page does not generate a winner or rating.
- | Supplier Category | Regulatory Status | Batch Testing Verification | Typical Purity Documentation | Legal Risk to Researcher | Operational Stability | Professional Assessment ||—|—|—|—|—|—|| US Peptides (defunct 2024) | Tier 3 grey-zone supplier. No FDA registration, no 503B status, no pharmacy board oversight | Generic COAs with no named lab, no chromatography data, no serialised lot tracking | Claimed 98%+ purity with no verifiable third-party confirmation | High. Purchasing from unregistered suppliers creates institutional liability for research labs | Collapsed in Q4 2024 under FDA enforcement. Zero operational continuity | Optimised for price and convenience, not compliance depth. Predictable failure under regulatory pressure || 503B Compounding Pharmacies | FDA-registered outsourcing facilities with routine inspections and state licensure | Named third-party labs (Janoshik, Colmaric) with serialised batch numbers and full chromatography reports | HPLC and mass spec data include
- The contrast is not subtle: suppliers operating outside regulatory oversight fail when enforcement increases. Suppliers operating within the framework adapt and continue.